Docstoc

Malignant Mesothelioma Therapeutics - Pipeline Assessment and

Document Sample
Malignant Mesothelioma Therapeutics - Pipeline Assessment and Powered By Docstoc
					Malignant Mesothelioma Therapeutics - Pipeline
Assessment and Market Forecasts to 2017




                                    Phone:    +44 20 8123 2220
                                    Fax:      +44 207 900 3970
                                    office@marketpublishers.com

                                    http://marketpublishers.com
                                                                                         Phone: +44 20 8123 2220
                                                                                         http://marketpublishers.com



Malignant Mesothelioma Therapeutics - Pipeline Assessment and
Market Forecasts to 2017
GlobalData

Date: Jul, 2011
Pages: 74
Price: US$ 2,000.00
ID: MD6DCE5E62DEN

Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Malignant Mesothelioma
Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of
information and analysis on the global malignant mesothelioma therapeutics market. The report identifies
the key trends shaping and driving the global malignant mesothelioma therapeutics market. The report also
provides insights on the prevalent competitive landscape and the emerging players expected to significantly
alter the market positioning of the current market leaders. Most importantly, the report provides valuable
insights on the pipeline products within the global malignant mesothelioma therapeutics sector. This report
is built using data and information sourced from proprietary databases, primary and secondary research
and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global (the US, the UK, France, Germany, Italy, Spain, Japan) malignant
mesothelioma therapeutics market was valued at $165m in 2010 and is forecast to grow at a compound
annual growth rate (CAGR) of 4.1% to reach $218m by 2017. The current malignant mesothelioma
therapeutics market is dominated by the chemotherapeutic regimen, Alimta (pemetrexed), which is a folate
antimetabolite in combination with cisplatin. The expected launch of NGR-hTNF (combination of a tumour
homing peptide (NGR) with the human tumour necrosis factor (hTNF), Onconase(ranpirnase) and Zolinza
(vorinostat) for the second-line treatment in 2014 will drive the market. However, the patent expiry of Alimta
in the forecast period will off-set the growth rate.

Scope
The report provides information on the key drivers and challenges of the malignant mesothelioma
therapeutics market. Its scope includes -


           Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) malignant
           mesothelioma therapeutics market revenues data from 2005 to 2010, forecast for seven years to
           2017.
           Pipeline analysis data providing a split across the different phases, mechanisms of action being
           developed and emerging trends by seven key markets. Pipeline candidates fall under major
           therapeutic classes such as Tyrosine kinases inhibitor, VEGF inhibitor, Immunomodulators.
           Analysis of the current and future competition in the seven key countries of the malignant
           mesothelioma therapeutics market. Key market players covered are MolMed S.p.A, Merck and Co.,
           Inc, Tamir Biotechnology Inc., Oxford Biomedica Plc, Canbas Co. Ltd, Bionomics Ltd, and Eisai
           Co.Ltd.
           Insightful review of the key industry drivers, restraints and challenges. Each trend is independently
           researched to provide a qualitative analysis of its implications.
           Key topics covered include strategic competitor assessment, market characterization, unmet needs
           and the implications for the malignant mesothelioma therapeutics therapeutics market.
           Analysis of key recent licensing and partnership agreements malignant mesothelioma therapeutics
           market
Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017                                 2
                                                                                         Phone: +44 20 8123 2220
                                                                                         http://marketpublishers.com




Reasons to buy

The report will enhance your decision making capability. It will allow you to -


           Develop and design your in-licensing and out-licensing strategies through a review of pipeline
           products and technologies and by identifying the companies with the most robust pipeline.
           Develop business strategies by understanding the trends shaping and driving the global malignant
           mesothelioma therapeutics market.
           Drive revenues by understanding the key trends, innovative products and technologies, market
           segments and companies likely to impact the global malignant mesothelioma therapeutics market in
           future.
           Formulate effective sales and marketing strategies by understanding the competitive landscape and
           by analyzing the performance of various competitors.
           Identify emerging players with potentially strong product portfolios and create effective
           counter-strategies to gain a competitive advantage.
           Organize your sales and marketing efforts by identifying the market categories and segments that
           present maximum opportunities for consolidations, investments and strategic partnerships.
           What’s the next big thing in the global malignant mesothelioma therapeutics market landscape? –
           Identify, understand and capitalize.



Table of Content
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 MALIGNANT MESOTHELIOMA THERAPEUTICS - INTRODUCTION

2.1 Disease Overview
2.2 Types of Malignant Mesothelioma
 2.2.1 Based on the Affected Organs
 2.2.2 Based on the Type of Histology:
2.3 Epidemiology
2.4 Etiology and Pathophysiology
2.5 Symptoms
2.6 Prognosis
2.7 Diagnosis
2.8 Staging and Treatment options
2.9 Treatment Options
2.10 GlobalData Pipeline Report Guidance

3 MALIGNANT MESOTHELIOMA THERAPEUTICS - MARKET CHARACTERIZATION

3.1 Malignant Mesothelioma Therapeutics Market Size, Global, 2005-2010
3.2 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Global
3.3 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - The US
3.4 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - The US
3.5 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - The UK
3.6 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - The UK
3.7 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - France
3.8 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - France

Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017                                 3
                                                                                         Phone: +44 20 8123 2220
                                                                                         http://marketpublishers.com


3.9 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - Germany
3.10 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Germany
3.11 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - Italy
3.12 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Italy
3.13 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - Spain
3.14 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Spain
3.15 Malignant Mesothelioma Therapeutics Market Size (2005-2010) - Japan
3.16 Malignant Mesothelioma Therapeutics Market Forecast (2010-2017) - Japan
3.17 Drivers and Barriers in the Malignant Mesothelioma Therapeutics Market
 3.17.1 Drivers for the Malignant Mesothelioma Therapeutics Market
 3.17.2 Barriers to the Malignant Mesothelioma Therapeutics Market
3.18 Opportunities and Unmet Needs Analysis
3.19 Key Takeaway

4 MALIGNANT MESOTHELIOMA THERAPEUTICS - COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Malignant Mesothelioma - Marketed Product Profiles
 4.3.1 Alimta (pemetrexed)
4.4 Key Takeaway

5 MALIGNANT MESOTHELIOMA THERAPEUTICS - PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Malignant Mesothelioma Therapeutics - Pipeline by Phases of Development
 5.3.1 Technology Trends Analytical Framework
 5.3.2 Malignant Mesothelioma Therapeutics - Phase III Pipeline
 5.3.3 Malignant Mesothelioma Therapeutics - Phase II Pipeline
 5.3.4 Malignant Mesothelioma Therapeutics - Phase I Pipeline
 5.3.5 Malignant Mesothelioma Therapeutics - Preclinical Pipeline
5.4 Malignant Mesothelioma Therapeutics - Clinical Pipeline by Mechanism of Action
5.5 Malignant Mesothelioma Therapeutics - Other Novel Mechanisms of Action
5.6 Malignant Mesothelioma Therapeutics - Promising Drugs under Clinical Development
5.7 Profiles of Promising Drugs in Clinical Development
 5.7.1 NGR-hTNF(combination of a tumour homing peptide (NGR) with the human tumour necrosis factor
(hTNF)
 5.7.2 Onconase (ranpirnase)
 5.7.3 Zolinza (vorinostat)
5.8 Key Takeaway

6 MALIGNANT MESOTHELIOMA THERAPEUTICS - CLINICAL TRIALS MAPPING

6.1 Clinical Trials by Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials by Overall Sponsors
6.5 Top Companies Participating in Therapeutics Clinical Trials

7 MALIGNANT MESOTHELIOMA THERAPEUTICS - STRATEGIC ASSESSMENT

7.1 Key Events Impacting the Future Market
7.2 Implications for Future Market Competition


Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017                                 4
                                                                                         Phone: +44 20 8123 2220
                                                                                         http://marketpublishers.com


8 MALIGNANT MESOTHELIOMA THERAPEUTICS - FUTURE PLAYERS

8.1 Introduction
8.2 Company Profiles
 8.2.1 MolMed S.p.A
 8.2.2 Merck and Co.
 8.2.3 Tamir Biotechnology Inc. (formerly known as Alfacell Corporation)
8.3 Malignant Mesothelioma - Other Future Players

9 MALIGNANT MESOTHELIOMA THERAPEUTICS - APPENDIX

9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
 9.3.1 Coverage
 9.3.2 Secondary Research
 9.3.3 Forecasting
 9.3.4 Primary Research
 9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

LIST OF TABLES

Table 1: Staging System of Malignant Mesothelioma
Table 2: Malignant Mesothelioma Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 3: Malignant Mesothelioma Therapeutics Market, Global, Forecast ($m), 2010-2017
Table 4: Malignant Mesothelioma Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 5: Malignant MesotheliomaTherapeutics Market, The US, Forecast ($m), 2010-2017
Table 6: Malignant Mesothelioma Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 7: Malignant Mesothelioma Therapeutics Market, The UK, Forecast ($m), 2010-2017
Table 8: Malignant Mesothelioma Therapeutics Market, France, Revenue ($m), 2005-2010
Table 9: Malignant Mesothelioma Therapeutics Market, France, Forecast ($m), 2010-2017
Table 10: Malignant Mesothelioma Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 11: Malignant Mesothelioma Therapeutics Market, Germany, Forecast ($m), 2010-2017
Table 12: Malignant Mesothelioma Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 13: Malignant Mesothelioma Therapeutics Market, Italy, Forecast ($m), 2010-2017
Table 14: Malignant Mesothelioma Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 15: Malignant Mesothelioma Therapeutics Market, Spain, Forecast ($m), 2010-2017
Table 16: Malignant Mesothelioma Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 17: Malignant Mesothelioma Therapeutics Market, Japan, Forecast ($m), 2010-2017
Table 18: Malignant Mesothelioma Therapeutics, Phase III Pipeline, 2011
Table 19: Malignant Mesothelioma Therapeutics, Phase II Pipeline, 2011
Table 20: Malignant Mesothelioma Therapeutics, Phase I Clinical Pipeline, 2011
Table 21: Malignant Mesothelioma Therapeutics, Preclinical Pipeline, 2011
Table 22: Malignant Mesothelioma Therapeutics, Other Mechanisms of Action
Table 23: Malignant Mesothelioma Therapeutics - Promising Drugs In Clinical Development, 2011
Table 24: Malignant Mesothelioma Therapeutics, Clinical Trials by Country
Table 25: Malignant Mesothelioma Therapeutics, Clinical Trials by Phase
Table 26: Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Status
Table 27: Malignant Mesothelioma Therapeutics, Clinical Trials by Overall Sponsors
Table 28: Malignant Mesothelioma Therapeutics -Top Companies Participating in Therapeutics Clinical
Trials, 2011
Table 29: MolMed S.p.A- Oncology Pipeline , 2011
Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017                                 5
                                                                                         Phone: +44 20 8123 2220
                                                                                         http://marketpublishers.com


Table 30: MolMed S.p.A - Deals 2009-2011
Table 31: Merck and Co. - Oncology Pipeline
Table 32: Merck and Co. - Deals 2009-2011
Table 33: Tamir Biotechnology - Oncology Pipeline
Table 34: Tamir Biotechnology - Deals 2009-2011
Table 35: Other Companies that have Molecules in the Pipeline

LIST OF FIGURES

Figure 1: Classification of Malignant Mesothelioma
Figure 2: Malignant Mesothelioma Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 3: Malignant Mesothelioma Therapeutics Market, Global, Forecast ($m), 2010-2017
Figure 4: Malignant Mesothelioma Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 5: Malignant Mesothelioma Therapeutics Market, The US, Forecast ($m), 2010–2017
Figure 6: Malignant Mesothelioma Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 7: Malignant Mesothelioma Therapeutics Market, The UK, Forecast ($m), 2010-2017
Figure 8: Malignant Mesothelioma Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 9: Malignant Mesothelioma Therapeutics Market, France, Forecast ($m), 2010-2017
Figure 10: Malignant Mesothelioma Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 11: Malignant Mesothelioma Therapeutics Market, Germany, Forecast ($m), 2010-2017
Figure 12: Malignant Mesothelioma Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 13: Malignant Mesothelioma Therapeutics Market, Italy, Forecast ($m), 2010-2017
Figure 14: Malignant Mesothelioma Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 15: Malignant Mesothelioma Therapeutics Market, Spain, Forecast ($m), 2010-2017
Figure 16: Malignant Mesothelioma Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 17: Malignant Mesothelioma Therapeutics Market, Japan, Forecast ($m), 2010-2017
Figure 18: Opportunity and Unmet Need in the Malignant Mesothelioma Therapeutics Market, 2011
Figure 19: Malignant Mesothelioma Therapeutics Market - Strategic Competitor Assessment, 2011
Figure 20: Malignant Mesothelioma Therapeutics, Pipeline by Phase of Clinical Development, 2011
Figure 21: Malignant Mesothelioma Therapeutics - Technology Trends Analytics Framework, 2011
Figure 22: Malignant Mesothelioma Therapeutics - Technology Trends Analytics Framework - Description,
2011
Figure 23: Malignant Mesothelioma Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 24: Malignant Mesothelioma Therapeutics - Clinical Trials by Country, 2011
Figure 25: Malignant Mesothelioma Therapeutics - Clinical Trials by Phase, 2011
Figure 26: Malignant Mesothelioma Therapeutics - Clinical Trials by Status, 2011
Figure 27: Malignant Mesothelioma Therapeutics - Overall Sponsors, 2011
Figure 28: Malignant Mesothelioma Therapeutics - Top Companies Participating in Therapeutics Clinical
Trials, 2011
Figure 29: Malignant Mesothelioma Therapeutics Market, Drivers and Restraints, 2011
Figure 30: Malignant Mesothelioma Therapeutics, Implications for Future Market Competition, 2011
Figure 31: Malignant Mesothelioma Therapeutics - Pipeline by Company, 2011
Figure 32: GlobalData Market Forecasting Model

COMPANIES MENTIONED

MolMed S.p.A
Merck and Co.
Tamir Biotechnology Inc




Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts to 2017                                 6
                                                                                                                              Phone: +44 20 8123 2220
                                                                                                                              http://marketpublishers.com




                                   I would like to order:

                                   Product name:         Malignant Mesothelioma Therapeutics - Pipeline Assessment and Market Forecasts
                                                         to 2017
                                   Product link:         http://marketpublishers.com/r/MD6DCE5E62DEN.html
                                   Product ID:           MD6DCE5E62DEN
                                   Price:                US$ 2,000.00 (Single User License / Electronic Delivery)

                                   If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com


                                   Payment

                                   To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button
                                   on product page http://marketpublishers.com/r/MD6DCE5E62DEN.html




                                   To pay by Wire Transfer, please, fill in your contact details in the form below:

                                   First name:
                                   Last name:
                                   E-mail:
                                   Company:
                                   Address:
                                   City:
                                   Zip/Post Code:
                                   Country:
                                   Tel:
                                   Fax:
                                   Your message:



                                                          * All fields are required



                                   Customer Signature _______________________________________

                                   Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at
                                   http://marketpublishers.com/docs/terms_conditions.html


                                   To place an order via fax simply print this form, fill in the information below
                                   and fax the completed form to +44 20 7900 3970




Powered by TCPDF (www.tcpdf.org)

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:5
posted:1/7/2012
language:
pages:7